Background
==========

Injuries to the musculoskeletal system, such as muscle damage resulting from extensive and unaccustomed exercise, trauma, dystrophies, ischemia and toxin exposition, have important functional impacts and therefore very significant consequences for daily activities. The same can be said for the sarcopenia observed in the elderly and the cachexia typically associated with chronic systemic diseases. Although our general understanding of muscle damage and regeneration has progressed significantly, the exact role of various signals and cells implicated in the process is still unclear in skeletal muscle.

Following muscle damage, there is an orchestrated recruitment of inflammatory cells, which produce pro- and/or anti-inflammatory signals leading initially to the removal of the damaged tissue and subsequently to the resolution of inflammation and tissue repair \[[@B1]-[@B5]\]. The key steps between inflammation and muscle healing include the resolution of inflammation and activation of myoblasts, which are present as quiescent muscle precursor cells in the form of satellite cells and stem cells in adult myofibers. Activated myoblasts migrate to the site of injury, proliferate, differentiate and fuse into myotubes to form new myofibers, eventually leading to restoration of form and function of the damaged muscle. Macrophages, mast cells, endothelial cells, fibroblasts and muscle fibers themselves can produce growth and transcription factors that influence myoblasts during muscle regeneration. Indeed, prostaglandins (PGs) and several growth factors such as fibroblast growth factors (FGFs), insulin-like growth factor-1 (IGF-1), transforming growth factor beta (TGF-β), epidermal growth factor (EGF), stem cell factor (SCF), and hepatocyte growth factor (HGF) have been identified as potent mediators of myogenesis \[[@B6]-[@B12]\]. However, the regulatory processes controlling early myoblast activation and subsequent proliferation remain only partially understood in skeletal muscle.

Mast cells are derived from bone marrow and their role has long been considered to be restricted to host defense and allergic reactions. However, it is now well documented that they can also modulate inflammation onset and resolution and also the repair phase \[[@B1],[@B13]-[@B15]\]. Increase in the density and the proportion of degranulated mast cells has been observed in skeletal muscle following various types of injury \[[@B1],[@B16],[@B17]\]. In models of bupivacaine-induced muscle injury and unloading-reloading muscle damage, mast cell stabilization caused a reduced neutrophil recruitment and a subsequent increase in the density of pro-inflammatory macrophages, confirming the implication of mast cells in modulating leukocyte infiltration \[[@B1],[@B16]\]. While several studies have looked at the role of mast cells in the inflammatory period, their potential action on the myogenic process has been less investigated.

It is known that mast cells can contribute to tissue repair and sometimes fibrosis by activating proliferation of epithelial \[[@B18]\] and smooth muscle cells \[[@B19]\] as well as fibroblasts \[[@B20]\], through the release of tryptase, a serine protease \[[@B21]\]. The tryptase-initiated signaling cascade supporting this proliferative response has been elucidated in fibroblasts \[[@B22],[@B23]\]. These studies have shown that tryptase modulates the proliferation of these cells through the cleavage of protease-activated receptor-2 (PAR-2) and a subsequent increase in COX-2 expression, a finding adding further importance to the role of COX-2 as an important actor for myogenesis in situation of skeletal muscle repair. There is now a long list of studies showing that COX-2 inhibition can impair skeletal muscle hypertrophy \[[@B24]\] and healing \[[@B25]\] processes and that COX-2 regulates growth of atrophied muscles \[[@B26]\] and early stages of skeletal muscle regeneration \[[@B27]\]. PAR-2 is a G-protein-coupled receptor whose activation requires the cleavage of the extracellular amino terminus of the receptor. PAR-2 receptor can respond to its known natural agonists such as tryptase and trypsin and also to synthetic agonists like SLIGKV. Whereas tryptase is specific to PAR-2 receptor, trypsin can also cleave and activate PAR-1 and -4 receptors. Data from one study suggest that synthetic PAR-2 agonists influence the proliferation of primary rodent neonatal myoblasts \[[@B28]\], but the effect of natural agonists and the mechanism underlying this phenomenon have not been documented and remain unknown.

Our objective was thus to document the existence of such mechanism in skeletal muscle cells. More specifically, we aimed to: 1) determine whether tryptase, via PAR-2 activation, stimulates L6 myoblast proliferation *in vitro*and 2) identify elements of the signaling cascade downstream of PAR-2. Our working hypothesis was that tryptase stimulates myoblast proliferation via cleavage of PAR-2 receptor and subsequent activation of COX-2. Our results confirmed the expression of PAR-2 receptor in L6 myoblasts and in satellite cells of mature rat skeletal muscle. In addition, we showed that activation of PAR-2 receptor leads to stimulation of L6 myoblast proliferation and that this effect is dependent on COX-2 activity.

Methods
=======

Animals
-------

Female Wistar rats weighing 125-150 g were used to determine the presence of PAR-2 in mature skeletal muscle. The treatment and care of these animals were approved by the Laval University Research Center Animal Care and Use Committee based on the guidelines of the Canadian Council on Animal Care.

Muscle homogenization of rat extensor digitorum longus (EDL) for PAR-2 probing
------------------------------------------------------------------------------

EDL muscles were homogenized at 4°C in lysis buffer containing 20 mM Tris, pH 7.5, 140 mM NaCl, 1 mM MgCl~2~, 1 mM CaCl~2~, 10% glycerol, 1% Igepal, 2 mM Na~3~VO~4~, 8.3 mM NaF, 0.2 mM PMSF and a cocktail of protease inhibitors P3840 from Sigma-Aldrich (St-Louis (MO), USA) using using a Polytron. Protein content was determined using bicinchoninic acid (BCA) protein assay reagent (Thermo Fisher Scientific, Rockforf (IL), USA).

Cell culture
------------

Subconfluent cultures of immortalized L6 rat skeletal myoblasts (ATCC, Manassas (VA), USA) were maintained in α-Mimimum Essential Medium (α-MEM) (Gibco, Carlsbad (CA), USA) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan (UT), USA).

Proliferation assay
-------------------

For measurement of proliferation rate, cells were seeded onto 96-well plate at a density of 3,000 cells/well in 65 μL of α-MEM containing 1% FBS and treated with or without tryptase (Sigma-Aldrich; St-Louis (MO), USA), trypsin (Sigma-Aldrich), PAR-2 synthetic activating peptide SLIGKV (Bachem Americas; Torrance (CA), USA), or prostaglandins PGF~2~α, PGE~2~or 15Δ-PGJ~2~(Cayman Chemical; Ann Arbor (MI), USA), at various doses for 48 h. When testing tryptase inhibition, tryptase was pre-incubated with a specific tryptase inhibitor, APC-366 (kind gift from American Peptides; Vista, (CA), USA), for 30 min at 37°C before addition to cells while COX-2 inhibition was tested by pre-incubation with a specific COX-2 inhibitor, NS-398, under the same conditions. The media was renewed after the first 24 h of incubation. In all experiments, the number of viable cells at the end of the experiment was determined by the use of CellTiter 96 Aqueous One Solution cell proliferation assay (Promega, Madison (WI), USA) according to the protocol proposed by the manufacturer.

Western Blot
------------

For analysis of COX-2 protein expression, adherent L6 cells were stimulated by tryptase (4 mU/ml) for 60 min or lipopolysaccharide (LPS) (10 μg/ml) (Sigma-Aldrich, St-Louis (MO), USA) for 3 h. For phospho-ERK1/2 protein expression, cells were deprived of serum for 4 h before being stimulated by tryptase (4 mU/ml) pre-incubated or not for 30 min at 37 °C with APC-366 (300 μM) or with NS-398 (100 μM) for periods ranging from 10 to 120 min. Cells were lysed in the lysis buffer previously described and protein content was determined by BCA protein assay reagent. Immunoblots were performed as described \[[@B29]\] by using primary antibodies PAR-2 (dilution 1:500) (Santa Cruz Biotechnology, Santa Cruz (CA), USA), COX-2 (dilution 1: 1,000) (Santa Cruz Biotechnology, Santa Cruz (CA), USA), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), p44/p42 MAPK (ERK1/2) (137F5) (dilution 1:1,000) (Cell Signaling Technology, Danvers (MA), USA) or GAPDH (1:1,000) (Santa Cruz Biotechnology, Santa Cruz (CA), USA) and their secondary antibodies which are anti-rabbit HRP conjugated (dilution 1:10,000) (Amersham, Buckinghamshire, England) for PAR-2, p44/42 MAPK and GAPDH, anti-goat HRP conjugated (dilution 1:10,000) (Santa Cruz Biotechnology) for COX-2 or anti-mouse HRP conjugated (dilution 1:10,000) (Santa Cruz Biotechnology) for phospho-p44/42 MAPK.

Reverse transcription and quantitative PCR (Q-PCR) analysis
-----------------------------------------------------------

For analysis of COX-2 gene expression, L6 cells were seeded in α-MEM 1% for 3 h before being stimulated by tryptase (4 mU/ml) for 10 to 120 min. RNA extraction was performed using RNeasy mini kit (Qiagen, Hilden, Germany) following the manufacturer protocol. 4 μg of total RNA was used for cDNA synthesis using Superscript II reverse transcription kit (Invitrogen Corporation, Carlsbad (CA), USA) in recommended conditions, using 500 ng of random hexamers (Roche, Nonnenwald, Germany). Primers used to amplify cDNA were designed using the free software Primer 3 (by Steve Rozen and Helen J, Skaletsky) available online at <http://frodo.wi.mit.edu/primer3/>. For COX-2, they were S: 5\'-CTGAGGGGTTACCACTTCCA-3\' and AS: 5\'-TGAGCAAGTCCGTGTTCAAG-3\' and for the house-keeping gene GAPDH, they were S: 5\'-AAACCCATCACCATCTTCCA-3\' and AS: 5\'-GTGGTTCACACCCATCACAA-3\'. The sequences were further analyzed with the software Amplify 3X (<http://engels.genetics.wisc.edu/amplify/index.html>) and synthesized at our institution. Q-PCR was performed by using a 36-well Rotor-Gene-3000 thermal cycler (Corbett Research, Mortlake, New South Wales, Australia) and results were analyzed with Rotor Gene version 6.0.27 software. cDNA (4 μl) from each sample were amplified by gene-specific primers described above (100 nM of each primer) in a 20 μl reaction containing 500 mM dNTP (Roche, Nonnenwald, Germany), 3 mM MgCl~2~(Sigma-Aldrich, St-Louis (MO), USA), SYBR^®^Green (1/30,000 dilution) (Invitrogen Corporation, Carlsbad (CA), USA), 5% DMSO (Sigma-Aldrich, St-Louis (MO), USA) and 1 U Taq polymerase (Roche, Nonnenwald, Germany). Thermal profile was: 95°C (15 s), 63°C (20 s), 72°C (25 s); 35 cycles. Fluorescence produced by SYBR^®^Green was measured at the end of the extension step of each cycle. At the end of the 35 cycles of amplification, the Melt^®^Procedure was performed to determine the specificity of the amplification. The fold increase of gene expression of COX-2 above GAPDH was evaluated by 2^ΔΔCT^relative quantification method described by Dussault et al. (2006) \[[@B30]\], where CT represents the cycle number where the fluorescence intensity reaches a threshold value in a PCR reaction expressed in the exponential phase.

Immunohistochemistry
--------------------

Transverse sections (10 μm thick) were obtained in the mid-belly section of the EDL muscle. Sections were adhered to positive charged microscope slides for immunostaining of PAR-2 and PAX-7 as previously described \[[@B31]\]. Briefly, sections were incubated with or without (negative control) primary anti-PAR-2 antibody (1:200) (Santa Cruz Biotechnology, Santa Cruz (CA), USA) or anti-PAX-7 antibody (1:100) overnight at 4°C and followed by a 1 h incubation with biotinylated anti-rabbit IgG and biotinylated anti-mouse IgG secondary antibodies (1:200), respectively. The monoclonal antibody PAX-7 developed by Kawakami, A. was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA 52242.

Measurement of COX activity
---------------------------

COX-2 activity was assessed directly by the use of a commercial COX activity assay kit (Cayman Chemical), allowing measurement of total COX activity and of the relative contribution of the two isoforms (COX-1 and -2) when using the selective COX-1 inhibitor SC-560. Briefly, cells were seeded in α-MEM supplemented with 10% FBS until reaching 80-90% confluence and then incubated for 2 h with or without trypsin (200 nM) for 30 min at 37°C before performing the test according to the procedure proposed by the manufacturer. To further validate these measurements, COX activity was also assessed indirectly via measurement of PGF~2~α production. Cells were seeded in α-MEM supplemented with 1% FBS until reaching 80-90% confluence. Cells were then incubated for 12 h with trypsin (200 nM) or tryptase (2 mU/ml), or pre-incubated with indomethacin (10 μM) (Sigma) or NS-398 (100 μM) for 30 min at 37°C before the addition of PAR-2 agonist. Production of PGF~2~α was assayed by enzyme immunoassay using a custom-made competitive ELISA as described previously \[[@B32]\].

Statistical analysis
--------------------

Data are presented as means ± s.e.m. Data were analyzed using Tukey-Kramer HSD multiple-comparison test when significant F ratios were obtained following two-way ANOVAs. P \< 0.05 was considered to be statistically significant.

Results
=======

Expression and functionality of PAR-2 receptor
----------------------------------------------

The expression of PAR-2 receptor was detectable in L6 cells and in rat skeletal muscle (EDL) (Figure [1A](#F1){ref-type="fig"}). The assessment of PAR-2 distribution by immunohistochemistry showed that PAR-2 is expressed at the membrane level of muscle fibers (Figure [1B](#F1){ref-type="fig"}, black arrows) and in satellite cells, which were identified by PAX-7 staining (Figure [1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). Specificity of PAR-2 staining was validated by the intense staining observed around blood vessel since endothelial cells are known to express PAR-2 receptor \[[@B33]\] (Figure [1B](#F1){ref-type="fig"}, white arrow). In L6 cells stimulated with tryptase, the proportion of phosphorylated ERK1/2, a downstream indicator of PAR-2 activation \[[@B23],[@B33]\], increased significantly compared to untreated cells whereas no significant response was seen when tryptase was pre-incubated with its specific inhibitor, APC-366 (Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). Pre-incubation with the COX-2 specific inhibitor NS-398 did not influence tryptase-induced phosphorylation of ERK1/2 (Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). These results confirmed that PAR-2: 1) is present and functional in L6 cells, 2) is expressed in satellite cells of mature skeletal muscle, and 3) can be activated by tryptase.

![**PAR-2 receptor expression in L6 myoblasts, in myofibers and in satellite cells of skeletal muscle**. A) Expression of PAR-2 receptor in L6 myoblasts and skeletal muscle (EDL) by western blot (representative sample of 4 separate experiments). B) Detection of PAR-2 protein by immunohistochemistry on EDL muscle myofibers (black arrows) and blood vessel (white arrow). C) and D) Immunohistochemistry performed on two consecutive sections showed that satellite cells identified by PAX-7 staining (C) also expressed PAR-2 receptor (D). The numbered cells 1 to 6 served to the localization of satellite cell on consecutives sections. E) Negative control of an immunohistochemistry performed without primary antibody PAR-2 or PAX-7. Bar = 50 μm.](1471-2474-12-235-1){#F1}

![**PAR-2 receptor functionality in L6 myoblasts**. A) Levels of phospho-ERK1/2 and total ERK1/2 by western blot following stimulation with tryptase, tryptase pre-incubated with its inhibitor APC-366 or with COX-2 inhibitor NS-398. GAPDH served as loading control. B) Quantification of the level of phospho-ERK1/2. Each data point represents the mean of at least 4 separate experiments (mean ± s.e.m). \* Significantly different from control (CTRL), *P*\< 0.05.](1471-2474-12-235-2){#F2}

Effect of tryptase, trypsin and activating peptide on L6 myoblast proliferation
-------------------------------------------------------------------------------

We next verified if PAR-2 activation by natural and synthetic agonists could stimulate cell proliferation. Tryptase increased proliferation of L6 cells by 35% above control at a concentration of 2 mU/ml (Figure [3A](#F3){ref-type="fig"}). Pre-incubation of tryptase with APC-366 caused a dose-dependent inhibition of the effect of tryptase on L6 cell proliferation (Figure [3B](#F3){ref-type="fig"}). L6 cell viability was not affected by APC-366 at the maximal concentration used (Figure [3C](#F3){ref-type="fig"}). To further confirm the implication of PAR-2 in the cascade modulating L6 myoblast proliferation, trypsin and the PAR-2 activating peptide SLIGKV were used. Both were found to stimulate L6 cell proliferation in a dose-dependent manner (Figure [3D](#F3){ref-type="fig"}, [3E](#F3){ref-type="fig"}). More precisely, trypsin increased proliferation by 76% while SLIGKV stimulated proliferation to a lower extent (26%). These results confirm that activation of PAR-2 receptor stimulates L6 myoblast proliferation.

![**Effect of PAR-2 agonists and tryptase inhibitor on L6 myoblast proliferation**. L6 myoblast proliferation following treatment with either A) tryptase, D) trypsin or E) PAR-2 synthetic activating peptide SLIGKV, while control wells received medium with 1% FBS only. B) Tryptase was pre-incubated with APC-366 where control wells (not pre-incubated with the inhibitor) represent 0% inhibition (not shown). C) L6 myoblasts were incubated either with APC-366 or NS-398 alone for 48 h to test for the possible cell toxicity. Each data point represents the mean of five separate experiments (mean ± s.e.m). \* Significantly different from control (CTRL) and ^\#^significantly different from APC-366 100 μM, *P*\< 0.05.](1471-2474-12-235-3){#F3}

Implication of PAR-2 and COX-2 in L6 myoblast proliferation
-----------------------------------------------------------

Since it has been demonstrated in fibroblasts that COX-2 is part of the signaling cascade leading to the stimulation of proliferation following PAR-2 activation, we investigated its putative role in the modulation of L6 myoblast proliferation. COX-2 was found to be constitutively expressed in L6 myoblasts and contrary to what was seen in fibroblasts, we were unable to detect any modulation of its expression following tryptase stimulation (Figure [4A](#F4){ref-type="fig"}). The same conclusion was reached by using Q-PCR to look at COX-2 mRNA level (data not shown). However, these results did not exclude the possibility of a modulation of the activity of COX-2. Measurement of COX-2 activity revealed a 7.1 fold increase in L6 cells stimulated with trypsin, whereas COX-1 activity was not increased significantly (Figure [4B](#F4){ref-type="fig"}). To further validate this finding, we looked at PGF~2~α production in L6 cells following PAR-2 activation and found that tryptase and trypsin led respectively to a 1.6 and 5.4 fold stimulation above control (Figure [4C](#F4){ref-type="fig"}), whereas the COX inhibitors NS-398 (COX-2 specific) and indomethacin (COX-1 and -2) abolished this effect to the same extent (data not shown). As could be predicted based on these findings, inhibiting COX-2 activity with NS-398 very significantly blunted the effect of tryptase and trypsin on cell proliferation (Figure [4D](#F4){ref-type="fig"}), an effect that could not be explained by a toxic effect of NS-398 since it did not impact on cell viability at the concentrations used (Figure [3C](#F3){ref-type="fig"}).

![**COX-2 expression and activity in L6 myoblasts**. A) COX-2 protein content was determined by western blotting in L6 myoblasts under basal conditions (CTRL) or in cells treated with tryptase (representative sample of 4 separate experiments) or with LPS. B) COX-1 and COX-2 activity following trypsin stimulation. C) COX-2 activity was measured by the production of PGF~2~α through enzyme immunoassay following tryptase and trypsin stimulation. D) L6 myoblast proliferation following incubation with increasing doses of NS-398 in presence of tryptase or trypsin where control wells (not pre-incubated with the inhibitor) represent 0% inhibition (not shown). E) L6 myoblast proliferation following incubation with increasing doses of 15Δ-PGJ~2~, while control wells received medium only. Each data point represents the mean of five separate experiments (mean ± s.e.m). \* Significantly different from control, *P*\< 0.05.](1471-2474-12-235-4){#F4}

The modulation of COX-2 activity following PAR-2 activation led us to test the influence of various PGs on L6 cell proliferation. Exogenous PGE~2~and PGF~2~α did not have any effect on cell proliferation, but 15Δ-PGJ~2~, a final product of COX-2-derived PGD~2~, stimulated L6 cell proliferation in a dose-dependent manner (Figure [4E](#F4){ref-type="fig"}). Taken together, these results suggest that modulation of COX-2 activity, and not its expression, is an intricate part of the cascade modulating L6 myoblast proliferation following PAR-2 activation and that 15Δ-PGJ~2~could be implicated.

Discussion
==========

Mast cells have been identified as an important actor in the inflammatory process following injury and allergic reactions. However, there is also strong evidence suggesting an implication of mast cells in tissue regeneration through stimulation of cell proliferation. For instance, mast cell tryptase and PAR-2 receptor signaling pathway can stimulate proliferation in some cell types and is even linked to uncontrolled cell proliferation in various diseases such as mastocytosis \[[@B34]\], fibrosis \[[@B22]\] and asthma \[[@B35]\]. While several observations point for a role of mast cells in processes governing inflammation and regeneration of skeletal muscle regeneration, the relevance of this signaling cascade in this tissue has yet to be addressed.

PAR-2 expression and activation by various agonists
---------------------------------------------------

Although the presence of PAR-2 receptors in skeletal muscle cells was previously observed in primary rodent neonatal myoblasts \[[@B28]\], we show here that immortalized L6 cells and satellite cells of rat mature skeletal muscle also express PAR-2 receptor, which is the only known receptor for tryptase \[[@B36]\]. The functionality of the receptor was also confirmed by the increased phospho-ERK1/2 content following tryptase-induced PAR-2 activation. Phospho-ERK1/2 is considered as a surrogate marker of the activation of PAR-2 \[[@B33]\] and is associated with tryptase-induced PAR-2 activation in human fibroblasts \[[@B22]\]. Tryptase inhibitor strongly annihilated the increase in phospho-ERK1/2 and the proliferative effect supporting the specificity of PAR-2 activation by tryptase. Lastly, the failure of NS-398 to modulate the phosphorylation of ERK1/2 following tryptase-induced PAR-2 activation suggests that this step is downstream of PAR-2 activation and upstream of COX-2 activation. These observations are in line with data from Frungieri et al. (2005) who demonstrated in human fibroblasts that the initial events of the tryptase/PAR-2 signaling pathway leading to cell proliferation rely on the activation of ERK1/2 \[[@B23]\]. We conclude that a functional PAR-2 receptor is expressed in L6 cells and that it can be stimulated by its two natural agonists and this leads to activation of ERK1-2.

Trypsin, a natural activator of PAR-2 \[[@B28]\], has been shown to mimic the proliferative effect of tryptase \[[@B37]-[@B39]\]. In our study, trypsin was a more potent stimulator of cell proliferation than tryptase, a finding previously observed \[[@B40]\]. One possible explanation for this difference is that trypsin is a PAR-1, -2 and -4 agonist while tryptase is PAR-2 specific. PAR-1 is expressed in myoblasts before fusion and PAR-1 agonists are able to stimulate proliferation of primary myoblasts \[[@B41]\]. As a result, we believe the response observed with trypsin in these experiments may have been the summation of both PAR-1 and -2 stimulations. The PAR-2 synthetic activating peptide (SLIGKV), on the other hand, induced a smaller response than tryptase and trypsin on L6 cells. This lower potency of SLIGKV is likely related to the inefficient presentation of the soluble peptide to its receptor binding domain leading to a less efficient stimulation compared to other molecules and/or to a shorter half-life in cell culture medium \[[@B36]\]. Another hypothesis to explain the difference between these three agonists is that PAR signaling can show \'functional selectivity\' or \'biased agonism\', a phenomenon leading to different signaling responses following activation of the same receptor by different agonists. Such behavior has been demonstrated for PAR-2 \[[@B42]\]. This phenomenon suggests that the effect observed following synthetic agonist stimulation does not correspond to a physiological response and reinforces the novelty of our study which documents the effect of natural PAR-2 agonists on skeletal muscle cell proliferation.

PAR-2 activation stimulates L6 myoblast proliferation through a COX-2 dependent mechanism
-----------------------------------------------------------------------------------------

In fibroblasts, cells with a very low constitutive expression of COX-2, activation of PAR-2 stimulates cell proliferation and leads to a very significant increase in the expression of COX-2 protein \[[@B22]\]. In L6 cells, we found a substantial constitutive expression of COX-2 protein, which was not modulated by stimulation of PAR-2 with tryptase. Constitutive COX-2 expression has also been reported in primary myoblast cultures and COX-2 activity was detected at basal level in these cells \[[@B26]\]. Interestingly, we also found that COX-2 is constitutively expressed in L6 myotubes and C2C12 myoblasts and myotubes (data not shown). COX-2 thus appears to be a constitutive component of not only proliferating myoblasts but also of differentiating myotubes in these two cell lines, observations again supporting its importance in muscle cell physiology.

The present data demonstrate that specific inhibition of COX-2 activity by NS-398 totally abolished the effect of tryptase and trypsin on L6 cell proliferation, a finding consistent with the growing number of papers showing that COX-2 inhibition can impact on skeletal muscle hypertrophy \[[@B24]\] and repair \[[@B25],[@B27]\] and primary satellite cell proliferation \[[@B43]\]. However, in most of these papers, the outcome measures following COX-2 inhibition were mainly at the functional level with no attempt at identifying the signaling cascade. In the present study, we show a functional effect of COX-2 inhibition on cell proliferation that we were able to link to a signaling cascade. The crucial role of COX-2 in this cascade was further confirmed by the direct assessment of COX activity which revealed that a concentration of trypsin stimulating cell proliferation led to a very significant increase in COX-2 activity. Because specific COX-2 inhibitor (NS-398) and non-specific COX-1 and -2 inhibitor (indomethacin) induced the same level of inhibition on PGF~2~α production and total COX activity, we conclude that only COX-2 is involved. Overall, these experiments solidly confirm the implication of COX-2 activity in the signaling cascade. This finding can be integrated to results showing that COX-2 derived PGs are important for myogenesis and essential for the regulation of muscle growth in stretch-induced myoblast proliferation \[[@B44]\] and in skeletal muscle hypertrophy \[[@B24]\] and regeneration following injury \[[@B27]\] and atrophy \[[@B26]\]. Pavlath et al. previously demonstrated that the COX-2 pathway regulates early stages of myofiber growth during muscle regeneration. They postulated that attenuated myonuclear addition caused by COX-2 inhibition could explain the impact on growth: since myonuclear addition depends on satellite cell activation and proliferation, we propose that the PAR-2 cascade we depict here is the link between COX-2 activity and myoblast activation and proliferation.

To further investigate the role of COX-2 activity, we tested the effect of three PGs on cell proliferation. Our observations showed that only 15Δ-PGJ~2~stimulated L6 cell proliferation while PGF~2~α and PGE~2~were found to be without effect. Evidence supporting the role of 15Δ-PGJ~2~in the resolution phase of inflammation is growing \[[@B45]-[@B47]\]; furthermore, it was shown to stimulate human fetal foreskin fibroblast proliferation \[[@B22]\]. In our model, the stimulating effect induced by 15Δ-PGJ~2~was very significant and further underlines the importance of COX-2 activity. 15Δ-PGJ~2~is traditionally known to exert its effect through PPARγ \[[@B22]\] and is considered its natural ligand. PPARγ expression can be detected in whole extracts of skeletal muscle \[[@B48],[@B49]\], but its specific expression in myoblasts has not been reported so far and the consensus is that it is not expressed in myocytes. However, there is growing evidence that 15Δ-PGJ~2~can have PPARγ-independent effects. For example, 15Δ-PGJ~2~can inhibit TNFα production by covalent binding of IκB kinase, thus keeping the transcription factor NF-κB in an inactive state \[[@B46],[@B50]\]. 15Δ-PGJ~2~can also act directly via DP1 receptor to accomplish its anti-inflammatory effects \[[@B47]\]. We must thus conclude that the effect of 15Δ-PGJ~2~on myoblast proliferation is likely PPARγ-independent and further work will be required to identify the target.

Conclusions
===========

In summary, we showed that the PAR-2 agonist tryptase can modulate L6 myoblast proliferation which involves the modulation of COX-2 activity and possibly 15Δ-PGJ~2~production. These data suggest that mast cells, via tryptase release, could be one of the components in the process triggering the proliferation of myoblasts, as it is the case with other cells such as fibroblasts, epithelial cells and smooth muscle cells. In addition, this study reveals that the largely reported influence of COX-2 on muscle regeneration may be explained, at least in part, by its implication in this signaling cascade supporting skeletal muscle cell proliferation. Clinically speaking, these data should be added to an extensive list of publications showing that cells classically limited to the inflammatory phase are also important for the regeneration phase of tissue repair.
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